1. Home
  2. GH vs SNN Comparison

GH vs SNN Comparison

Compare GH & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Guardant Health Inc.

GH

Guardant Health Inc.

HOLD

Current Price

$91.48

Market Cap

13.3B

Sector

Health Care

ML Signal

HOLD

Logo Smith & Nephew SNATS Inc.

SNN

Smith & Nephew SNATS Inc.

HOLD

Current Price

$34.15

Market Cap

14.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GH
SNN
Founded
2011
1856
Country
United States
United Kingdom
Employees
N/A
16988
Industry
Medical Specialities
Industrial Specialties
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.3B
14.3B
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
GH
SNN
Price
$91.48
$34.15
Analyst Decision
Strong Buy
Hold
Analyst Count
19
2
Target Price
$119.79
$36.25
AVG Volume (30 Days)
2.1M
736.5K
Earning Date
05-07-2026
03-16-2026
Dividend Yield
N/A
2.19%
EPS Growth
6.74
N/A
EPS
N/A
N/A
Revenue
$982,021,000.00
N/A
Revenue This Year
$33.30
$8.58
Revenue Next Year
$28.27
$5.60
P/E Ratio
N/A
$64.97
Revenue Growth
32.88
N/A
52 Week Low
$36.36
$26.02
52 Week High
$120.74
$38.79

Technical Indicators

Market Signals
Indicator
GH
SNN
Relative Strength Index (RSI) 53.42 57.17
Support Level $89.32 $32.03
Resistance Level $101.77 $37.23
Average True Range (ATR) 5.54 0.57
MACD 0.65 0.28
Stochastic Oscillator 69.78 83.48

Price Performance

Historical Comparison
GH
SNN

About GH Guardant Health Inc.

Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

About SNN Smith & Nephew SNATS Inc.

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Share on Social Networks: